Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Nanomedicine. 2015 Aug 15;11(8):1893–1907. doi: 10.1016/j.nano.2015.07.015

Figure 1.

Figure 1

Chronology of first clinical approvals of nanomedicines after the introduction of the EPR effect. Myocet is approved only in Europe and Canada, Lipusu in China, Genexol-PM in South Korea and PICN in India. The size of nanoparticles given in parenthesis is approximate. *Abraxane becomes ~10 nm in size from ~130 nm following disintegration in the blood 17. The size of Lipusu is not available.